Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
14
Recruiting, industry sponsors, Gastroenterology and liver, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed310
14 trials
Showing 1 to 14, recently updated first.
- A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07527910 · 204 participants (planned) · Start May 22, 2026 · Primary completion Mar 15, 2030
Drug: ALN-PNP; Tirzepatide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Sites: Tucson, Arizona; Coronado, California; Pasadena, California · 10 sites in all
- A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).Pivotal-lookingRecruiting
Eupraxia Pharmaceuticals Inc.Industry
NCT05608681 · 117 participants (planned) · Start Mar 31, 2023 · Primary completion Dec 2026
Drug: EP-104GI · For: Eosinophilic Esophagitis
Sites: Sydney, Australia; Brisbane, Australia; Maroochydore, Australia · 33 sites in all
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver DiseasePivotal-lookingRecruiting
Hudson BiotechIndustry
NCT07481734 · 120 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: Tesamorelin; Placebo · For: Metabolic Associated Steatotic Liver Disease; Nonalcoholic Steatohepatitis; Hepatic Steatosis
Sites: Shenzhen, China
EccogeneIndustry
NCT07288138 · 160 participants (planned) · Start Dec 15, 2025 · Primary completion Sep 15, 2027
Drug: Placebo; ECC4703 and 2 more · For: Metabolic Dysfunction-associated Steatohepatitis
Sites: Chandler, Arizona; Peoria, Arizona; Tucson, Arizona · 70 sites in all
- Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07631637 · 360 participants (planned) · Start Jul 6, 2026 · Primary completion Jan 29, 2029
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis; MASH
Sites: Tucson, Arizona; Pasadena, California; Rialto, California · 24 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06920043 · 42 participants (planned) · Start Apr 9, 2025 · Primary completion Jul 3, 2028
Drug: Efimosfermin; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease
Sites: Chandler, Arizona; Mesa, Arizona; Tucson, Arizona · 30 sites in all
- A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07545772 · 342 participants (planned) · Start Apr 29, 2026 · Primary completion Jul 2027
Drug: LY3537031; Placebo · For: Irritable Bowel Syndrome; Constipation
Sites: Mesa, Arizona; Anaheim, California; Lancaster, California · 70 sites in all
- A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07545759 · 531 participants (planned) · Start May 6, 2026 · Primary completion Sep 2027
Drug: LY3537031; Placebo · For: Irritable Bowel Syndrome; Diarrhea
Sites: Mesa, Arizona; Anaheim, California; Lancaster, California · 89 sites in all
- Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07841977 · 132 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 2028
Drug: Seladelpar; PTM Seladelpar and 4 more · For: Primary Biliary Cholangitis
Sites: Colorado Springs, Colorado; Lakewood Rch, Florida; Atlanta, Georgia · 4 sites in all
- A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07519395 · 420 participants (planned) · Start Apr 8, 2026 · Primary completion Mar 9, 2027
Drug: Placebo; Camlipixant · For: Irritable Bowel Syndrome
Sites: Anniston, Alabama; Guntersville, Alabama; Mobile, Alabama · 114 sites in all
- A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05648214 · 172 participants (planned) · Start Dec 27, 2022 · Primary completion Aug 10, 2027
Drug: ALN-PNP; Placebo (PB) · For: Healthy Volunteers; Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Sites: Glendale, California; Los Angeles, California; Miami, Florida · 6 sites in all
Hinova Pharmaceuticals Inc.Industry
NCT07308548 · 80 participants (planned) · Start Oct 11, 2025 · Primary completion Aug 13, 2026
Drug: HP515 10 mg Tablet; Placebo of HP515 10 mg Tablet and 2 more · For: NAFLD (Non-alcoholic Fatty Liver Disease)
Sites: Beijing, China; Chengdu, China
Polaris GroupIndustry
NCT05842512 · 60 participants (planned) · Start Sep 13, 2023 · Primary completion Dec 31, 2027
Drug: ADI-PEG20 · For: Nonalcoholic Steatohepatitis (NASH)
Sites: Chiayi City, Taiwan; Kaohsiung, Taiwan; Keelung, Taiwan · 10 sites in all
- Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)Pivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06569524 · 120 participants (planned) · Start Sep 14, 2023 · Primary completion Dec 2026
Drug: TQA2225/AP025 or TQA2225/AP025 Placebo 25mg; TQA2225/AP025 or TQA2225/AP025 Placebo 50mg · For: Non-alcoholic Steatohepatitis
Sites: Lu'an, China; Beijing, China; Fuzhou, China · 53 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.